采用起始低剂量缓慢加量策略开始别嘌醇治疗者痛风发作的预测因素
该研究为12个月双盲安慰剂对照非劣效试验的事后分析,参与者按1:1随机接受秋水仙碱0.5 mg每日或安慰剂治疗前6个月。多因素分析显示,开始别嘌醇前1个月内有痛风发作及别嘌醇100 mg起始剂量与最初6个月痛风发作风险显著相关;停用研究药物后6个月内,曾接受秋水仙碱、停药前1个月至少1次发作及第6个月血尿酸≥0.36 mmol/L为预测因素。
要点
- 开始别嘌醇前1个月内有发作(OR 2.65)及别嘌醇100 mg起始剂量(OR 3.21)与最初6个月痛风发作风险显著相关。
- 停用秋水仙碱或安慰剂后6个月内,曾接受秋水仙碱(OR 2.95)、停药前1个月至少1次发作(OR 5.39)及第6个月血尿酸≥0.36 mmol/L(OR 2.85)为预测因素。
- 作者认为抗炎预防可能最适合针对开始别嘌醇前1个月内有发作且以100 mg每日起始者;初始6个月内仍有发作且未达血尿酸目标者可能需要更长预防期。
核心结论
- 采用「起始低剂量缓慢加量」策略开始别嘌醇时,抗炎预防可能最适合针对开始别嘌醇前1个月内有痛风发作且以别嘌醇100 mg每日起始者。
- 对于开始别嘌醇最初6个月内仍有痛风发作且尚未达到血尿酸目标者,可能需要更长预防期。
研究设计与样本
- 12个月双盲安慰剂对照非劣效试验的事后分析,参与者按1:1随机接受秋水仙碱0.5 mg每日或安慰剂治疗前6个月。
- 采用多因素logistic回归模型识别试验最初6个月和最后6个月痛风发作的独立预测因素。
主要发现
- 多因素分析显示,最初6个月痛风发作风险与开始别嘌醇前1个月内发作(OR 2.65,95%CI 1.36-5.17)及别嘌醇100 mg起始剂量(OR 3.21,95%CI 1.41-7.27)显著相关。
- 试验最后6个月(停用秋水仙碱或安慰剂后)任何痛风发作的预测因素为:曾接受秋水仙碱(OR 2.95,95%CI 1.48-5.86)、停药前1个月内至少1次发作(OR 5.39,95%CI 2.21-13.15)、第6个月血尿酸≥0.36 mmol/L(OR 2.85,95%CI 1.14-7.12)。
临床怎么用
- 作者认为,采用「起始低剂量缓慢加量」策略开始别嘌醇时,抗炎预防可能最适合针对开始别嘌醇前1个月内有痛风发作且以别嘌醇100 mg每日起始者。
- 作者认为,对于开始别嘌醇最初6个月内仍有痛风发作且尚未达到血尿酸目标者,可能需要更长预防期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The study objective was to determine predictors of gout flare when commencing allopurinol using the "start-low go-slow" dose escalation strategy. METHODS: A post hoc analysis of a 12-month double-blind placebo-controlled noninferiority trial with participants randomized 1:1 to colchicine 0.5 mg daily or placebo for the first six months was undertaken. Multivariate logistic regression models were used to identify independent predictors of gout flares in the first and last six months of the trial. RESULTS: Multivariable analysis revealed a significant association between risk of a gout flare in the first six months and flare in the month before starting allopurinol (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.36-5.17) and allopurinol 100 mg starting dose (OR 3.21, 95% CI 1.41-7.27). The predictors of any gout flares in the last six months of the trial, after stopping colchicine or placebo, were having received colchicine (OR 2.95, 95% CI 1.48-5.86), at least one flare in the month before stopping study drug (OR 5.39, 95% CI 2.21-13.15), and serum urate ≥0.36 mmol/L at month 6 (OR 2.85, 95% CI 1.14-7.12). CONCLUSION: Anti-inflammatory prophylaxis when starting allopurinol using the "start-low go-slow" dose escalation strategy may be best targeted at those who have had a gout flare in the month before starting allopurinol and are commencing allopurinol 100 mg daily. For those with ongoing gout flares during the first six months of starting allopurinol who have not yet achieved serum urate target, a longer period of prophylaxis may be required.
引用
- Stamp LK, Horne A, Mihov B, et al. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy. Arthritis Care Res (Hoboken). 2024. PMID: 38766703. doi:10.1002/acr.25376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。